ClinicalTrials.gg
CompletedNCT04223193TEMPO-2Updated Nov 21, 2025Results posted

Flexible-Dose Trial in Early Parkinson's Disease (PD)

A Phase 3 interventional study of Tavapadon and Placebo in Parkinson Disease, sponsored by AbbVie. Completed at 53 sites in 13 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.

Enrollment
4th of 11
304 · median 57
Started
2020
with 2 others
Phase 3
4 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
4 of 11
AbbVie

Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 4th largest by enrollment, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 6th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About tavapadon

tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing tavapadon in Parkinson Disease as a file.
02

Study summary

The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinsonian Disorders
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Movement Disorders
  • Neurodegenerative Diseases
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male and female participants aged 40 to 80 years, inclusive, at the time of signing the form (ICF).
  • Sexually active men or women of must agree to use acceptable (at minimum) or highly effective , or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment.
  • Participants who are capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
  • Participants with a diagnosis of PD that is consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria.
  • Participants with modified Hoehn and Yahr stage 1, 1.5, or 2.
  • Participants with disease duration (from time of diagnosis) of less than (\<) 3 years and disease progression in the 3 years before signing the ICF.
  • Participants with an MDS-UPDRS Part II score >=2 and Part III score >=10 at the Screening Visit and at the Baseline Visit.
  • Participants with early PD who, in the opinion of the investigator, require pharmacologic intervention for disease management.
  • Participants who are treatment naive or have a history of prior incidental treatment with dopaminergic agents (including L-Dopa and dopamine receptor agonist medications) for \<3 months in total but not within 2 months of the Baseline Visit. Prior and concurrent use of MAO-B inhibitors is permitted if use was initiated >90 days before the Baseline Visit and the dosage will remain stable for the duration of the trial (ie, no change in the MAO-B inhibitor dose is permitted during the trial).
  • Participants who are willing and able to refrain from any PD medications that are not permitted by the protocol (including dopaminergic agents) throughout participation in the trial.

Key Exclusion Criteria:

  • Participants with a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supra nuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug-induced or post stroke parkinsonism).
  • Participants with a history of nonresponse or insufficient response to L-Dopa at therapeutic dosages.
  • Participants with a history or current diagnosis of a impulse control disorder (Disruptive, Impulse Control, and Conduct Disorder per ).
  • Participants with the presence of or history of brain tumor, hospitalization for severe head trauma, epilepsy (as defined by the International League Against Epilepsy), or seizures.
  • Participants with a history of psychosis or hallucinations within the previous 12 months.
  • Participants who answer "yes" on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR Participants who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide.
  • Participants with substance abuse or dependence disorder, including alcohol, benzodiazepines, and opioids, but excluding nicotine, within the past 6 months (180 days).
  • Participants with dementia or cognitive impairment that, in the judgement of the investigator, would exclude the participant from understanding the ICF or participating in the trial.
  • Participants with any condition that could possibly affect drug absorption, including bowel resections, bariatric weight loss surgery, or gastrectomy (this does not include gastric banding).
  • Participants who have a positive result for (HIV) antibodies, surface antigen (HbsAg), or virus (HCV) antibodies at screening.
  • Participants with a history of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias that are not controlled with medical and/or surgical intervention; second- or third-degree atrioventricular block; sick sinus syndrome; severe or unstable angina; or congestive heart failure within the last 12 months. A recent (less than or equal to [\<=] 12 months) history of myocardial infarction with secondary arrhythmias is exclusionary regardless of the therapeutic control.
  • Participants with a history of neuroleptic malignant syndrome.
  • Participants who are currently receiving moderate or strong inducers or CYP3A4 inhibitors (except for topical administration).
  • Participants with a positive urine drug screen for illicit drugs are excluded and may not be retested or rescreened. Participants with a positive urine drug screen resulting from use of marijuana (any Tetrahydrocannabinol [THC]-containing product), prescription, or over-the-counter medications or products that, in the investigator's documented opinion, do not signal a clinical condition that would impact the safety of the participant or interpretation of the trial results may continue evaluation for the trial following consultation and approval by the medical monitor.
  • Participants with a (MoCA) score \<26.
  • Participants with clinically significant orthostatic hypotension (eg, syncope).
  • Participants with a 12-lead demonstrating a interval >450 msec.
  • Participants with moderate or severe renal impairment ( as estimated by Cockcroft-Gault formula \<30 mL/min or on dialysis).
  • Participants with any of the following abnormalities in clinical laboratory tests at the Screening Visit, as assessed by the central laboratory and confirmed by a single repeat measurement, if deemed necessary:

    • (AST) or Alanine Aminotransferase (ALT) >=3 × Upper Limit Normal ().
    • Total >=1.5 × ULN. Participants with a history of Gilbert's syndrome may be eligible provided they have a value \<ULN for direct bilirubin.
  • Participants with other abnormal laboratory test results, vital sign results, or ECG findings unless, in the judgment of the investigator, the findings are not medically significant and would not impact the safety of the participants or the interpretation of the trial results.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    Tavapadon

    Participants will receive tavapadon tablet titrated up to 15 milligram (mg) once daily (QD) orally for 27 weeks.

    Drug: Tavapadon

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to tavapadon tablet QD orally for 27 weeks.

    Drug: Placebo

Interventions

  • Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.

    Also known as: PF-06649751, CVL-751

  • DrugPlacebo

    Participants will receive placebo matching to tavapadon QD orally for 27 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score

    The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.

    Time frame: Week 26

Secondary outcomes

  1. Change From Baseline in the MDS-UPDRS Part II Score

    The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.

    Time frame: Week 26

  2. Percentage of Responders With "Much Improved" or "Very Much Improved" on Participant Global Impression of Change (PGIC)

    The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

    Time frame: Week 26

  3. Change From Baseline in the MDS-UPDRS Parts II and III Combined Score

    The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  4. Change From Baseline in the MDS-UPDRS Parts I, II and III Combined Score

    The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 1, 2, and 3 combined is the sum of Part 1, Part 2, and Part 3 scores at each assessment time for each participant. The combined score assesses 44 items with score range: 0-236.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  5. Change From Baseline in the MDS-UPDRS Parts I, II and III Individual Score

    The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  6. Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score

    The Global Impression - Severity of Illness (CGI-S) Score is a clinician's impression of a participant's severity of illness on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (normal) to 7 (among the most extremely ill participants). Higher values represent a worse outcome.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  7. Clinical Global Impression - Improvement (CGI-I) Score

    The Clinical Global Impression - Improvement (CGI-I) Score is a clinician's impression of how much the participant's illness has improved or worsened relative to the baseline on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  8. Change From Baseline in the PGIC Score

    The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

    Time frame: Week 5, 8, 11, 14, 18, 22, 26, and 27

  9. Change From Baseline in the Epworth Sleepiness Scale (ESS)

    The ESS is an 8-question, participant questionnaire that is intended to measure daytime sleepiness. It assesses the likelihood of dozing off or falling asleep in the following common situations: sitting and reading, sitting inactive in a public place as a passenger in a car for an hour or more without stopping for a break, lying down to rest when circumstances permit, sitting and talking to someone, sitting quietly after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a light. Each situation is rated on a 4-point (0-3) scale with scores ranging from 0 (would never nod off) to 3 (high chance of nodding off). Higher values represent a worse outcome. A negative change from baseline represents an improvement in daytime sleepiness. The total ESS score range was 0 - 24.

    Time frame: Week 26

  10. Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)

    QUIP-RS is a questionnaire for impulse-compulsive disorders in Parkinson's disease rating scale to assess impulse control disorders (ICD). The QUIP-RS has 4 primary questions that pertain to commonly reported thoughts, urges/ desires, and behaviors associated with ICDs, each of which is applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). The QUIP-RS uses a 5-point Likert scale (score 0-4 \[0 means "never" and 4 means "very often"\] for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (frequency) of symptoms. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112. A higher score indicating greater severity of symptoms. A negative change from baseline represents an improvement in ICDs.

    Time frame: Week 26

  11. Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation (SI) categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.

    Time frame: Week 27

  12. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug until 190 days following last dose of study drug.

07

Results

Posted Nov 21, 2025

Participant flow

Participant flow — Overall Study
MilestonePlaceboTavapadon
Started153151
Completed13094
Not completed2357
Withdrew: Adverse event636
Withdrew: Lack of efficacy22
Withdrew: Lost to follow-up11
Withdrew: Failure to meet continuation criteria10
Withdrew: Treatment with prohibited concomitant medications30
Withdrew: Non-compliance with study drug01
Withdrew: Physician decision01
Withdrew: Protocol violation11
Withdrew: Site terminated by sponsor13
Withdrew: Withdrawal by subject56
Withdrew: Other36

Outcome measures

PrimaryChange From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.

Time frame:
Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score
score on a scalePlaceboTavapadon
Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score-1.2 ± 0.89-10.3 ± 0.99
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -9.1 · 95% CI -11.7 to -6.5
SecondaryChange From Baseline in the MDS-UPDRS Part II Score

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.

Time frame:
Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in the MDS-UPDRS Part II Score
score on a scalePlaceboTavapadon
Change From Baseline in the MDS-UPDRS Part II Score0.0 ± 0.30-1.5 ± 0.33
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0007 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -1.5 · 95% CI -2.4 to -0.6
SecondaryPercentage of Responders With "Much Improved" or "Very Much Improved" on Participant Global Impression of Change (PGIC)

The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Percentage of Responders With "Much Improved" or "Very Much Improved" on Participant Global Impression of Change (PGIC)
ParticipantsPlaceboTavapadon
Percentage of Responders With "Much Improved" or "Very Much Improved" on Participant Global Impression of Change (PGIC)2546
Statistical analysis
  • Placebo vs Tavapadon · Mixed Models Analysis · p = <0.0001 · Odds ratio (or): 3.942 · 95% CI 2.209 to 7.037
SecondaryChange From Baseline in the MDS-UPDRS Parts II and III Combined Score

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 2 and 3 combined is the sum of Part 2 score and Part 3 score at each assessment time for each participant. The combined score assesses 31 items with score range: 0-184.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the MDS-UPDRS Parts II and III Combined Score
score on a scalePlaceboTavapadon
Week 5-2.1 ± 0.58-5.5 ± 0.63
Week 8-2.4 ± 0.64-8.5 ± 0.69
Week 11-2.3 ± 0.71-9.5 ± 0.77
Week 14-2.2 ± 0.76-10.3 ± 0.84
Week 18-2.2 ± 0.85-10.0 ± 0.93
Week 22-1.3 ± 0.82-10.1 ± 0.92
Week 26-1.2 ± 0.89-10.3 ± 0.99
Week 27-1.2 ± 0.89-10.4 ± 0.99
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -9.1 · 95% CI -11.7 to -6.5
SecondaryChange From Baseline in the MDS-UPDRS Parts I, II and III Combined Score

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function. Parts 1, 2, and 3 combined is the sum of Part 1, Part 2, and Part 3 scores at each assessment time for each participant. The combined score assesses 44 items with score range: 0-236.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the MDS-UPDRS Parts I, II and III Combined Score
score on a scalePlaceboTavapadon
Week 5-2.7 ± 0.67-5.2 ± 0.72
Week 8-3.2 ± 0.73-8.3 ± 0.79
Week 11-3.2 ± 0.82-9.3 ± 0.89
Week 14-3.0 ± 0.88-10.4 ± 0.96
Week 18-2.9 ± 0.96-10.1 ± 1.05
Week 22-1.8 ± 0.96-10.1 ± 1.07
Week 26-1.6 ± 1.03-9.9 ± 1.15
Week 27-1.8 ± 1.03-10.2 ± 1.14
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -8.3 · 95% CI -11.3 to -5.3
SecondaryChange From Baseline in the MDS-UPDRS Parts I, II and III Individual Score

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating tool was used to follow longitudinal course of Parkinson's Disease. It was made up of 4 parts: Part 1: Non-motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 2: Motor aspects of experiences of daily living (13 items. Score range: 0-52); Part 3: Motor examination (18 items. Score range: 0-132); Part 4: Motor complications (6 items. Score range: 0-24. Part 4 was not collected in this trial). Each item has 0-4 rating on scale from 0 (normal) to 4 (severe). Higher values represent a worse outcome. A negative change from baseline represents an improvement in motor function.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the MDS-UPDRS Parts I, II and III Individual Score
score on a scalePlaceboTavapadon
Part I: Week 5-0.6 ± 0.230.4 ± 0.25
Part I: Week 8-0.8 ± 0.250.2 ± 0.27
Part I: Week 11-0.8 ± 0.250.2 ± 0.27
Part I: Week 14-0.7 ± 0.25-0.1 ± 0.27
Part I: Week 18-0.7 ± 0.25-0.2 ± 0.27
Part I: Week 22-0.5 ± 0.270.0 ± 0.30
Part I: Week 26-0.4 ± 0.290.3 ± 0.32
Part I: Week 27-0.6 ± 0.280.2 ± 0.31
Part II: Week 5-0.6 ± 0.22-1.0 ± 0.24
Part II: Week 8-0.4 ± 0.23-1.5 ± 0.25
Part II: Week 11-0.2 ± 0.26-1.4 ± 0.28
Part II: Week 14-0.4 ± 0.26-1.7 ± 0.29
Part II: Week 18-0.3 ± 0.27-1.5 ± 0.30
Part II: Week 220.2 ± 0.29-1.4 ± 0.32
Part II: Week 260.0 ± 0.30-1.5 ± 0.33
Part II: Week 270.0 ± 0.30-1.3 ± 0.34
Part III: Week 5-1.5 ± 0.48-4.5 ± 0.52
Part III: Week 8-2.0 ± 0.53-7.0 ± 0.58
Part III: Week 11-2.2 ± 0.58-8.1 ± 0.64
Part III: Week 14-1.9 ± 0.63-8.6 ± 0.69
Part III: Week 18-1.9 ± 0.69-8.4 ± 0.77
Part III: Week 22-1.5 ± 0.68-8.7 ± 0.76
Part III: Week 26-1.2 ± 0.71-8.9 ± 0.80
Part III: Week 27-1.2 ± 0.71-9.0 ± 0.80
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0766 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: 0.7 · 95% CI -0.1 to 1.6
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.0007 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -1.5 · 95% CI -2.4 to -0.6
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -7.6 · 95% CI -9.7 to -5.6
SecondaryChange From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score

The Global Impression - Severity of Illness (CGI-S) Score is a clinician's impression of a participant's severity of illness on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (normal) to 7 (among the most extremely ill participants). Higher values represent a worse outcome.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score
score on a scalePlaceboTavapadon
Week 50.0 ± 0.04-0.2 ± 0.05
Week 80.0 ± 0.05-0.2 ± 0.05
Week 110.0 ± 0.05-0.3 ± 0.06
Week 140.0 ± 0.05-0.3 ± 0.05
Week 180.0 ± 0.05-0.3 ± 0.06
Week 220.0 ± 0.05-0.4 ± 0.06
Week 260.0 ± 0.06-0.4 ± 0.06
Week 270.0 ± 0.05-0.3 ± 0.06
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -0.4 · 95% CI -0.5 to -0.2
SecondaryClinical Global Impression - Improvement (CGI-I) Score

The Clinical Global Impression - Improvement (CGI-I) Score is a clinician's impression of how much the participant's illness has improved or worsened relative to the baseline on a 7-point scale. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · units on a scale
Clinical Global Impression - Improvement (CGI-I) Score
units on a scalePlaceboTavapadon
Week 53.6 ± 0.063.3 ± 0.07
Week 83.5 ± 0.073.1 ± 0.08
Week 113.5 ± 0.083.0 ± 0.09
Week 143.6 ± 0.082.9 ± 0.09
Week 183.7 ± 0.092.8 ± 0.10
Week 223.6 ± 0.092.8 ± 0.10
Week 263.7 ± 0.102.7 ± 0.11
Week 273.7 ± 0.092.8 ± 0.11
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -1.0 · 95% CI -1.3 to -0.7
SecondaryChange From Baseline in the PGIC Score

The Patient Global Impression of Change (PGIC) is a 7-point response scale. The participant response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" was assessed. Scores ranged from 1-7 on a scale of 1 (very much improved) to 7 (very much worse). Higher values represent a worse outcome.

Time frame:
Week 5, 8, 11, 14, 18, 22, 26, and 27
Reported as:
Least squares mean · score on a scale
Change From Baseline in the PGIC Score
score on a scalePlaceboTavapadon
Week 53.5 ± 0.083.3 ± 0.09
Week 83.6 ± 0.093.1 ± 0.09
Week 113.6 ± 0.093.1 ± 0.10
Week 143.6 ± 0.102.9 ± 0.11
Week 183.7 ± 0.102.9 ± 0.12
Week 223.7 ± 0.102.9 ± 0.12
Week 263.8 ± 0.112.8 ± 0.12
Week 273.8 ± 0.112.8 ± 0.12
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = <0.0001 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -1.0 · 95% CI -1.3 to -0.7
SecondaryChange From Baseline in the Epworth Sleepiness Scale (ESS)

The ESS is an 8-question, participant questionnaire that is intended to measure daytime sleepiness. It assesses the likelihood of dozing off or falling asleep in the following common situations: sitting and reading, sitting inactive in a public place as a passenger in a car for an hour or more without stopping for a break, lying down to rest when circumstances permit, sitting and talking to someone, sitting quietly after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a light. Each situation is rated on a 4-point (0-3) scale with scores ranging from 0 (would never nod off) to 3 (high chance of nodding off). Higher values represent a worse outcome. A negative change from baseline represents an improvement in daytime sleepiness. The total ESS score range was 0 - 24.

Time frame:
Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Epworth Sleepiness Scale (ESS)
score on a scalePlaceboTavapadon
Change From Baseline in the Epworth Sleepiness Scale (ESS)-0.1 ± 0.22-0.1 ± 0.24
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.9795 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: 0.0 · 95% CI -0.6 to 0.6
SecondaryChange From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)

QUIP-RS is a questionnaire for impulse-compulsive disorders in Parkinson's disease rating scale to assess impulse control disorders (ICD). The QUIP-RS has 4 primary questions that pertain to commonly reported thoughts, urges/ desires, and behaviors associated with ICDs, each of which is applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). The QUIP-RS uses a 5-point Likert scale (score 0-4 \[0 means "never" and 4 means "very often"\] for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (frequency) of symptoms. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112. A higher score indicating greater severity of symptoms. A negative change from baseline represents an improvement in ICDs.

Time frame:
Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)
score on a scalePlaceboTavapadon
Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)-1.9 ± 0.31-2.0 ± 0.34
Statistical analysis
  • Placebo vs Tavapadon · Mixed-effect Model Repeated Measurement · p = 0.8916 (LS Means, SE, difference from placebo, and CI's are estimated using a mixed effects repeated measures model with fixed effects for treatment group, visits, treatment by visit interaction and MAO-B inhibitor use with the baseline value as a covariate.) · Ls mean of difference: -0.1 · 95% CI -0.9 to 0.8
SecondaryColumbia-Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation (SI) categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.

Time frame:
Week 27
Reported as:
Count of participants · Participants
Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsPlaceboTavapadon
Participants With Any Suicidal Ideations05
Participants With Any Suicidal Behaviors00
Participants With Any Suicidal Behaviors or Ideations05
Participants With Non-Suicidal Self-Injurious Behavior00
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug until 190 days following last dose of study drug.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlaceboTavapadon
Any TEAE84115
TESAE27

Adverse events

Collected over All-cause mortality were reported from enrollment until 4 weeks after the end of study. Treatment-emergent adverse events and serious adverse events were collected from first dose of study drug until 4 weeks after the last dose of study drug. Mean duration on study drug was 176.7 and 144.5 days for Placebo and Tavapadon, respectively. Median time on follow up (median time subjects were followed) was 200 and 198 days for Placebo and Tavapadon, respectively.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/153 (0%)2/153 (1.3%)59/153 (38.6%)
Tavapadon0/151 (0%)7/151 (4.6%)99/151 (65.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboTavapadon
FALLINJURY, POISONING AND PROCEDURAL COMPLICATIONS0/1532/151
FEMORAL NECK FRACTUREINJURY, POISONING AND PROCEDURAL COMPLICATIONS0/1531/151
HEAD INJURYINJURY, POISONING AND PROCEDURAL COMPLICATIONS0/1531/151
JOINT INJURYINJURY, POISONING AND PROCEDURAL COMPLICATIONS0/1531/151
PRESYNCOPENERVOUS SYSTEM DISORDERS0/1531/151
REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROMENERVOUS SYSTEM DISORDERS0/1531/151
DEPRESSIONPSYCHIATRIC DISORDERS0/1531/151
HYPERTENSIONVASCULAR DISORDERS0/1531/151
HYPERCHROMIC ANAEMIABLOOD AND LYMPHATIC SYSTEM DISORDERS1/1530/151
HYPERHIDROSISSKIN AND SUBCUTANEOUS TISSUE DISORDERS1/1530/151
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPlaceboTavapadon
NAUSEAGASTROINTESTINAL DISORDERS5/15345/151
HEADACHENERVOUS SYSTEM DISORDERS8/15325/151
DIZZINESSNERVOUS SYSTEM DISORDERS5/15324/151
TREMORNERVOUS SYSTEM DISORDERS13/1533/151
VOMITINGGASTROINTESTINAL DISORDERS0/15312/151
FATIGUEGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS1/15312/151
DYSGEUSIANERVOUS SYSTEM DISORDERS0/15312/151
ASTHENIAGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS2/1538/151
FALLINJURY, POISONING AND PROCEDURAL COMPLICATIONS3/1538/151
COVID-19INFECTIONS AND INFESTATIONS8/1535/151

Baseline characteristics

ITT Population includes all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboTavapadonTotal
Mean62.6 ± 9.4363.1 ± 8.9862.9 ± 9.20
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTavapadonTotal
Female6867135
Male8584169
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTavapadonTotal
Hispanic or Latino11516
Not Hispanic or Latino137141278
Unknown or Not Reported5510
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTavapadonTotal
American Indian or Alaska Native101
Asian151732
Native Hawaiian or Other Pacific Islander000
Black or African American202
White134134268
More than one race000
Unknown or Not Reported101
MDS-UPDRS Score at Baseline (Parts II and III Combined)
MDS-UPDRS Score at Baseline (Parts II and III Combined)(units on a scale)PlaceboTavapadonTotal
Mean30.0 ± 11.1131.1 ± 11.2130.5 ± 11.16
08

Study locations

53 sites
  • Fresno, California
    Fresno, California 93710, United States
  • Boca Raton, Florida
    Boca Raton, Florida 33487, United States
  • Maitland, Florida
    Maitland, Florida 32751, United States
  • Ocala, Florida
    Ocala, Florida 34470, United States
  • Winter Park, Florida
    Winter Park, Florida 32792, United States
  • Boston Neuro Research Center
    North Dartmouth, Massachusetts 02747, United States
  • Albany, New York
    Albany, New York 12208, United States
  • Syracuse, New York
    Syracuse, New York 13210, United States
  • Cincinnati, Ohio
    Cincinnati, Ohio 45212, United States
  • Cleveland, Ohio
    Cleveland, Ohio 44195, United States
  • Memphis, Tennessee
    Memphis, Tennessee 38157, United States
  • Cypress, Texas
    Cypress, Texas 77429, United States
  • Houston, Texas
    Houston, Texas 77030, United States
  • Lubbock, Texas
    Lubbock, Texas 79410, United States
  • Round Rock, Texas
    Round Rock, Texas 78681, United States
  • Richmond, Virginia
    Richmond, Virginia 23229, United States
  • Richmond, Virginia
    Richmond, Virginia 23233, United States
  • Kirkland, Washington
    Kirkland, Washington 98034, United States
  • Macquarie Park, New South Wales
    Sydney, New South Wales 2109, Australia
  • Marseille, France
    Marseille, France 13385, France
  • Nantes CEDEX 1
    Nantes, Nantes 44093, France
  • Toulouse Cedex 9
    Toulouse, Toulouse 31059, France
  • Bochum
    Bochum, Bochum 44791, Germany
  • Gera
    Gera, Gera 07551, Germany
  • Muenchen
    München, Muenchen 81377, Germany
  • Berlin
    Berlin, State of Berlin 12163, Germany
  • Budapest
    Budapest, Budapest 1135, Hungary
  • Pecs
    Pécs, Hungary 7623, Hungary
  • Tatabanya
    Tatabánya, 2800, Hungary
  • Cassino
    Cassino, Cassino 03043, Italy
  • Milano
    Milan, Milano 20132, Italy
  • Rome
    Rome, Rome 00133, Italy
  • Rozzano Milano
    Rozzano, 20089, Italy
  • Torino
    Torino, 10126, Italy
  • Cracow
    Krakow, Cracow 31-505, Poland
  • Katowice
    Katowice, Katowice 40-097, Poland
  • Siemianowice Slaskie
    Siemianowice Śląskie, Siemianowice Slaskie 41-100, Poland
  • Centrum Medyczne NEUROMED
    Bydgoszcz, 85-163, Poland
  • Centrum Medyczne Hope Clinic Sebastian Szklener
    Lublin, 20-701, Poland
  • Belgrade
    Belgrade, Belgrade 11000, Serbia
  • Dongdaemun-gu, Seoul
    Seoul, Dongdaemun-gu 02447, South Korea
  • Haeundae-gu, Busan
    Busan, Haeundae-gu 48108, South Korea
  • Songpa-gu, Seoul
    Seoul, Songpa-gu 05505, South Korea
  • Barcelona
    Barcelona, Barcelona 08035, Spain
  • Móstoles, Madrid
    Madrid, Madrid 28938, Spain
  • Zhongzheng, Taipei
    Zhongzheng, Taipei 100225, Taiwan
  • Zhongzheng, Taipei
    Zhongzheng, Taipei 112062, Taiwan
  • Ratchathewi, Bangkok
    Ratchathewi, Bangkok 10400, Thailand
  • Khlong Luang, Pathum Thani
    Khlong Luang, Changwat Pathum Thani 12120, Thailand
  • Nai Muang, Ubon Ratchathani
    Nai Muang, Changwat Ubon Ratchathani 34000, Thailand
  • Kiev
    Kiev, Kyiv City 04114, Ukraine
  • Lviv
    Lviv, Lviv Oblast 79010, Ukraine
  • Vinnitsa
    Vinnitsa, Vinnitsa 21050, Ukraine
09

References and documents

Publications

  • Fernandez HH, Bhatia P, Cloud L, Fietzek UM, Matarazzo M, Molho E, Peckham E, Tarakad A, Combs C, Leoni M, Chang I, Tringali S, Boiser J, Sanchez R, Zadikoff C. Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2026 Aug;25(8):721-730. doi: 10.1016/S1474-4422(26)00215-2. PubMed 42456682 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Oct 2024, 56 months.

Results were first posted in Nov 2025, 1 year 1 month after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 56 months is above that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2020
First posted
Jan 10, 2020
StartActual
Jan 6, 2020
Primary completionActual
Oct 1, 2024
CompletionActual
Oct 1, 2024
Results first posted
Nov 21, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04223193
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 10, 2020
Start date
Jan 6, 2020
Primary completion
Oct 1, 2024
Completion
Oct 1, 2024
Results posted
Nov 21, 2025
Last update
Nov 21, 2025

Study contacts

ABBVIE Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion